APELLIS PHARMACEUTICALS INC (APLS) Stock Income Statement
NASDAQ:APLS - Nasdaq - US03753U1060 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 781.37M | 396.59M | 75.40M | 66.60M | 250.60M | |||
| Cost Of Goods | 117.72M | 58.51M | 5.60M | 5.20M | 25.10M | |||
| Gross Profit | 663.64M | 338.08M | 69.80M | 61.40M | 225.60M | |||
| Operating Expenses | 828.62M | 855.20M | 664.40M | 597.60M | 439.30M | |||
| Research and Development | 327.57M | 354.39M | 387.20M | 420.90M | 299.90M | |||
| Selling, General, and Administrative Expenses | 501.05M | 500.81M | 277.20M | 176.80M | 139.40M | |||
| Operating Income | -164.98M | -517.12M | -594.60M | -536.30M | -213.70M | |||
| Interest Income/Expense | -29.57M | -8.65M | -23.70M | -110.50M | -128.80M | |||
| Other Income/Expense | -2.17M | -727.00K | -300.00K | 1.40M | -500.00K | |||
| Non Recurring Items | 0.00 | 0.00 | -32.90M | -100.60M | N/A | |||
| Income Before Taxes | -196.72M | -526.50M | -651.50M | -746.00M | -343.00M | |||
| Income Tax | 1.16M | 2.13M | 700.00K | 400.00K | 1.80M | |||
| Net Income | -197.88M | -528.63M | -652.20M | -746.40M | -344.90M | |||
| EBITDA | -163.18M | -515.34M | -593.05M | -534.92M | -213.06M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.60 | -4.45 | -6.15 | -8.84 | -4.59 | |||
| Non GAAP EPS | -1.45 | -4.48 | -6.13 | -8.93 | -4.72 | |||
| Statistics | ||||||||
| Gross Profit Margin | 84.93% | 85.25% | 92.57% | 92.19% | 90.02% | |||
| Profit Margin | -25.32% | -133.29% | -864.99% | -1120.72% | -137.63% | |||
| Operating Profit Margin | -21.11% | -130.39% | -788.59% | -805.26% | -85.28% | |||
All data in USD